Can biomarkers predict chemosensitivity in CRS-HIPEC patients?

IF 2.7 Q3 ONCOLOGY

Colorectal Cancer Pub Date : 2019-12-01 DOI:10.2217/crc-2019-0015

Josephine Hendrikson, J. Tan, C. Ong

引用次数: 1

查看原文本刊更多论文

生物标志物能预测CRS-HIPEC患者的化疗敏感性吗？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Colorectal Cancer ONCOLOGY-

自引率

0.00%

发文量

期刊介绍： Colorectal cancer is a major cause of morbidity and mortality, particularly in the developed world. Risk factors for colorectal cancer are on the rise in many countries; populations are aging, and obesity and diabetes are increasing. National screening programs are helping to detect cancer while it is still curable; however, colorectal cancer remains the third leading cause of cancer deaths in the USA and options are still limited for those with more advanced disease. Consequently, colorectal cancer is a major research priority for government, pharmaceutical companies and non-profit organizations. Research into diagnosis and optimum treatment of the disease is progressing rapidly, with new advances reported every day. Colorectal Cancer presents reviews, analysis and commentary. on all aspects of colorectal cancer.